Who gets to decide who receives experimental medical treatments?

MIT Technology Review, August 10, 2023: This excellent news article by MIT Technology Review asks “Who decides who receives experimental medical treatments” and are FDA’s standards for accelerated approval too low for Duchenne Muscular Dystrophy, cancer, and other diseases. We call accelerated approval a disaster.

Read More »

Questions remain about new drug for hot flashes

Leaps. Org, Jul 27, 2023: This news story discusses the May, 2023, FDA approval of fezolinetant (brand name Veozah™) to treat hot flashes caused by menopause. While the drug was shown to slightly reduce the frequency and severity of hot flashes per day, NCHR and other experts question if these changes are sufficient to justify any risks and the high cost. We also suggest possible alternative strategies to deal with hot flashes.

Read More »